PPIDT00324
Drug Information
| Name | Benralizumab |
|---|---|
| Sequence | EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB12023 |
| Type | biotech |
| Indication | Benralizumab is indicated as a maintenance treatment of patients 6 years or older with severe asthma and an eosinophilic phenotype.[L50652] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Parenteral; Subcutaneous |
30 MG
|
| Injection, solution | Subcutaneous |
10 mg/0.5mL
|
| Injection, solution | Subcutaneous |
30 mg
|
| Injection, solution | Subcutaneous |
30 mg/1mL
|
| Solution | Subcutaneous |
30 mg / mL
|
| Solution | Subcutaneous |
30 mg
|
| Injection, solution | Subcutaneous |
|
| Injection, solution | — |
30 mg/ml
|
| Injection, solution | Subcutaneous |
30 mg/ml
|
| Solution | Subcutaneous |
3000000 mg
|
| Injection, solution | — |
30 mg/1ml
|